クローン病患者の非炎症部空腸組織におけるヒトαディフェンシ６の減少 by Hayashi, Ryohei
For Peer Review
 
 
 
 
 
 
Reduced human α-defensin 6 in non-inflamed jejunal tissue 
of Crohn’s disease patients 
 
 
Journal: Inflammatory Bowel Diseases 
Manuscript ID IBD-15-0459.R1 
Wiley - Manuscript type: Original Research Articles - Basic Science 
Date Submitted by the Author: 26-Sep-2015 
Complete List of Authors: Hayashi, Ryohei; Graduate School of Biomedical & Health Sciences, 
Hiroshima University, Department of Gastroenterology and Metabolism 
Tsuchiya, Kiichiro; Graduate School Tokyo Medical and Dental University, 
Gastroenterology and Hepatology 
Fukushima, K ita; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology 
Horita, Nobukatsu; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology 
Hibiya, Shuji; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology 
Kitagaki, Keisuke; Graduate School Tokyo Medical and Dental University, 
Department of Pathology 
Negi, Mariko; Graduate School Tokyo Medical and Dental University, 
Department of Pathology 
Itoh, Eisaku; Graduate School Tokyo Medical and Dental University, 
Department of Pathology 
Akashi, Takumi; Graduate School Tokyo Medical and Dental University, 
Department of Pathology 
Eishi, Yoshinobu; Graduate School Tokyo Medical and Dental University, 
Department of Pathology 
Okada, Eriko; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology 
Araki, Akihiro; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology 
Ohtsuka, Kazuo; Graduate School Tokyo Medical and Dental University, 
Department of Endoscopic Diagnosis and Therapy 
Fukuda, Shinji; RIKEN Center for Integrative Medical Sciences (IMS) 
AMED-CREST, Japan Agency for Medical Research and Development, 
Laboratory for Intestinal Ecosystem; Keio University, Institute for 
Advanced Biosciences 
Ohno, Hiroshi; RIKEN Center for Integrative Medical Sciences (IMS) AMED-
CREST, Japan Agency for Medical Research and Development, Laboratory 
for Intestinal Ecosystem 
Okamoto, Ryuichi; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology; Graduate School Tokyo 
Medical and Dental University, Center for Stem Cell and Regenerative 
Medicine; Graduate School Tokyo Medical and Dental University, Center for 
Stem Cell and Regenerative Medicine 
Inflammatory Bowel Diseases
For Peer Review
Nakamura, Testuya; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology; Graduate School Tokyo 
Medical and Dental University, Department of Advanced Therapeutics for 
Gastrointestinal Diseases 
Tanaka, Shinji; Graduate School of Biomedical & Health Sciences, 
Hiroshima University, Endoscopy and Medicine 
Chayama, Kazuaki; Graduate School of Biomedical & Health Sciences, 
Hiroshima University, Department of Gastroenterology and Metabolism 
Watanabe, Mamoru; Graduate School Tokyo Medical and Dental University, 
Department of Gastroenterology and Hepatology 
Keywords: 
atonal homolog 1, mapping biopsy, Paneth cell, mucosal barrier, 
inflammatory bowel disease 
  
 
 
Page 1 of 74 Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
1 
Reduced human α-defensin 6 in non-inflamed jejunal tissue of Crohn’s disease 
patients  
 
Ryohei Hayashi
1, 2
, Kiichiro Tsuchiya
2
, Keita Fukushima
2
, Nobukatsu Horita
2
, Shuji 
Hibiya
2
, Keisuke Kitagaki
3
, Mariko Negi
3
, Eisaku Itoh
3
,
 
Takumi Akashi
3
, Yoshinobu 
Eishi
3
, Eriko Okada
2
, Akihiro Araki
2
, Kazuo Ohtsuka
4
, Shinji Fukuda
5, 6
, Hiroshi Ohno
5
, 
Ryuichi Okamoto
2, 7
, Tetsuya Nakamura
2. 8
, Shinji Tanaka
9
, Kazuaki Chayama
1
 and 
Mamoru Watanabe
2
 
 
1
Department of Gastroenterology and Metabolism, 
9
Endoscopy and Medicine, Graduate 
School of Biomedical & Health Sciences, Hiroshima University,
 2
Department of 
Gastroenterology and Hepatology, 
3
Department of Pathology, 
4
Department of 
Endoscopic Diagnosis and Therapy, 
7
Center for Stem Cell and Regenerative Medicine 
and 
8
Department of Advanced Therapeutics for Gastrointestinal Diseases, Graduate 
School Tokyo Medical and Dental University, 
5
Laboratory for Intestinal Ecosystem, 
RIKEN Center for Integrative Medical Sciences (IMS) AMED-CREST, Japan Agency 
for Medical Research and Development, 
6
Institute for Advanced Biosciences, Keio 
University. 
 
Correspondence 
Kiichiro Tsuchiya, M.D., Ph.D.  
Associated Professor  
Department of Gastroenterology and Hepatology Graduate School, Tokyo Medical and 
Dental University 
Page 2 of 74Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
2 
1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan  
Tel: +81-3-5803-5974 Fax: +81-3-5803-0268  
e-mail: kii.gast@tmd.ac.jp 
 
Word count: 4842 
Number of tables/figures: 6 figures. 
Quantity of supplementary data: 5 
 
Running title: HD6 is decreased in non-inflamed jejunum of CD patients. 
 
Key Words: Atoh1, mapping biopsy, Paneth cell, mucosal barrier, inflammatory bowel 
disease 
 
Abbreviations: Atoh1, Atonal homolog 1; IBD, inflammatory bowel disease; CD, 
Crohn’s disease; UC, ulcerative colitis; HD6; human α-defensin 6; AMPs, secretion of 
antimicrobial peptides; TCF4, T-cell-specific transcription factor 4; HD, human α-
defensin. 
 
Grant support: This study was supported in part by grants-in-aid for Scientific 
Research, 23130506, 24590935, 25114703, 25130704 and 26221307 from the Japanese 
Ministry of Education, Culture, Sports, Science and Technology; Japan Foundation for 
Applied Enzymology; the Health and Labor Sciences Research Grants, 14526073 from 
the Japanese Ministry of Health, Labor and Welfare (MHLW); Research Center 
Network for Realization of Regenerative Medicine from Japan Science and Technology 
Page 3 of 74 Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3 
Agency (JST). Advanced Research and Development Programs for Medical Innovation 
from Japan Agency for Medical Research and Development (AMED) 
 
Page 4 of 74Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
Abstract 
Background & Aims: Mucosal barrier dysfunction is considered a critical component 
of Crohn’s disease (CD) pathogenesis following the identification of susceptibility 
genes. However, the precise mechanism underlying mucosal barrier dysfunction has not 
yet been elucidated. We therefore aimed to elucidate the molecular mechanism 
underlying the expression of human α-defensin 6 (HD6) in CD patients.    
Methods: 
HD6 expression was induced by the transfection of an atonal homolog 1 (Atoh1) 
transgene and was assessed by RT-PCR. The HD6 promoter region targeted by Atoh1 
and β-catenin was determined by reporter analysis and ChIP assay. HD5 / HD6 / Atoh1 
/ β-catenin expression in non-inflamed jejunal samples collected by balloon endoscopy 
from 15 CD and 9 non-IBD patients were assessed by immunofluorescence.  
Results: 
Both promoter activity and gene expression of HD6 was significantly upregulated by 
the Atoh1 transgene in human colonic cancer cell line. We identified a TCF4 binding 
site and an E-box site critical for the regulation of HD6 transcriptional activity by 
directly binding of Atoh1 in the 200-bp HD6 promoter region. The treatment with beta-
catenin inhibitor also decrease of HD6 promoter activity and gene expression. 
Moreover, HD6 expression, but not HD5 expression, was found to be decreased in non-
inflamed jejunal regions from CD patients. In HD6-negative crypts, nuclear 
accumulation of β-catenin was impaired.  
 
Conclusions: 
HD6 expression was found to be regulated by cooperation between Atoh1 and β-catenin 
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within the HD6 promoter region. Down-regulation of HD6 in non-inflamed mucosa 
may contribute to mucosal barrier dysfunction of CD patients. 
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Introduction  
 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the commonest causes of 
inflammatory bowel disease (IBD)(1). In Western countries, there has been a recent 
focus on the contribution of mucosal barrier dysfunction to CD pathogenesis(2) due to 
the discovery of susceptibility genes, including nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2)(3), autophagy-related protein 16-1 (ATG16L1)(4), 
and X-box-binding protein-1 (XBP1)(5). In particular, the function of Paneth cells in 
forming the mucosal barrier against gut microbiota has been considered as a critical 
factor in CD onset(6). Paneth cell function is broadly divided into two categories: the 
recognition of bacteria and the secretion of antimicrobial peptides (AMPs)(7). Although 
various agents are secreted by Paneth cells, the precise mechanism underlying the 
production of individual AMPs has yet to be clarified for the majority of AMPs. We 
previously reported upregulation of sPLA2 expression following activation of Notch 
signaling(8). The expression of human defensin 5 (HD5) is reportedly regulated by 
binding of β-catenin to T-cell-specific transcription factor 4 (TCF4)-binding sites(9). 
Human defensin 6 (HD6) is also a member of the α-defensin family and is expressed by 
Paneth cells(10). Because of poor antibacterial potency, the molecular mechanism 
underlying HD6 expression has yet not been assessed(11). However, HD6 has recently 
been reported to act as a mucosal barrier by forming “nanonets” to trap bacteria(12). 
Furthermore, reduced form of HD6 has been shown to have a bactericidal effect 
because HD6 expression is also important in the formation of the mucosal barrier(13). 
In this study, we aimed to elucidate the molecular mechanism underlying HD6 
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expression and determine the potential role of HD6 in CD pathogenesis. We then 
investigated the mechanisms regulating HD6 transcriptional activity and expression 
contributing to decreased HD6 levels in non-inflamed jejunum of CD patients using 
mapping biopsies of the entire small intestine. 
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Materials and Methods 
 
Cell culture and chemicals 
Human colon cancer-derived SW480 and DLD-1 cells were grown in Dulbecco’s 
modified Eagle medium (Life Technologies, Grand Island, NY, USA) supplemented 
with 10% fetal bovine serum and 0.01% penicillin-streptomycin. Except where 
indicated otherwise, cells were seeded at a density of 5×10
5
 cells/mL in each 
experiment. Cell cultures and plasmid DNA transfections were performed as previously 
described(14). 5µM Calphostin C (Sigma-Aldrich, St. Louis, MO, USA) was added to 
media to inhibit β-catenin/TCF4 complex formation(15). 
 
Plasmids  
An mCherry-Atoh1 vector was generated by inserting the ATOH1 gene into the 
mCherry DNA template PG27188 (DNA 2.0, Menlo Park, CA, USA). An ATOH1 gene 
mutant vector (5SA-Atoh1) was constructed by PCR-mediated mutagenesis by 
replacing nucleotide cording for five serine residues, TCC (160–162) and AGC (172–
174, 328–330, 340–342, 352–354), with nucleotides coding for the alanine residue, 
GCC. The Atoh1-lentivirus vector was generated by inserting the PCR-amplified 
mCherry-Atoh1 or mCherry-5SA-Atoh1 plasmid into pLenti 6.4 (Invitrogen) as 
previously described(16). Lentiviruses were generated according to the procedure 
manual. A HD6 reporter plasmid was generated by cloning a 1000- and 241-bp 
sequence of the human HD6 gene, HD6, into a pGL4 basic vector (Promega, Madison, 
WI, USA). A mutant HD6 promoter was constructed using polymerase chain reaction 
(PCR)-mediated mutagenesis to delete TCF4-binding sites and E-box sites. The primer 
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sequences used in this study are summarized in Supplementary Table S1. 
 
 
Quantitative Real-time PCR  
Total RNA was isolated using an RNeasy Micro Kit (QIAGEN), according to the 
manufacturer’s instructions. One-microgram aliquots of total RNA were used for cDNA 
synthesis in 20 µl reaction volumes. One microliter of cDNA was amplified with 
SYBR-Green in 20 µl reactions as previously described(14). The primer sequences used 
in this study are summarized in Supplementary Table S1. The amount of mRNA 
expression was normalized by β-actin.  
 
 
Luciferase Assays  
SW480 cells were seeded in six-well plate culture dishes and transfected with 4 µg of 
reporter plasmid along with 10 ng of pRL-TK plasmid (Promega). Cells were harvested 
36 h after transfection, lysed by three cycles of freezing and thawing, and the luciferase 
activities of each sample, measured in arbitrary units, were normalized against Renilla 
luciferase activities as previously described(14).  
 
Chromatin Immunoprecipitation (ChIP) Assay  
ChIP assays were performed as previously described with some modifications. DLD1 
and DLD1-mCherry-Atoh1-5SA cells were seeded onto a 150-mm dish. 
Immunoprecipitation was performed overnight at 4°C with 10 µg of an anti-mCherry 
(Clontech, USA), normal mouse immunoglobulin G (sc-2025; Santa Cruz 
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Biotechnology, Santa Cruz, CA, USA), or an anti-histone H3 antibody (Abcam, 
Cambridge, MA, USA). Genomic DNA fragments in immunoprecipitated samples were 
analyzed by PCR using primers designed against genomic DNA regions relative to the 
translation start site (Supplementary Table S1). Equal amounts of DNA samples were 
analyzed by conventional PCR in parallel using the following parameters: denaturation 
at 94°C for 15 s; annealing at 60°C for 30 s; and extension at 68°C for 60 s for 45 
cycles. Products were resolved by agarose gel electrophoresis, stained with ethidium 
bromide, and visualized using an ImageQuant TL system (GE Healthcare, Milwaukee, 
WI, USA).
 
 
 
Human Small Intestinal Tissue  
Human tissue specimens were obtained from 15 CD and 9 non-IBD patients with an 
indication to undergo double balloon endoscopy or single balloon endoscopy at Tokyo 
Medical and Dental University Hospital. Patient’s information is shown in 
Supplementary Table S2. Non-IBD patients were performed endoscopy because of the 
obscure gastrointestinal bleeding. To analyze the structure of normal small intestine, we 
selected biopsy specimens from non-IBD patients who showed no abnormality in small 
intestine(17). Written informed consent was obtained from all included patients and this 
study was approved by the Ethics Committee of Tokyo Medical and Dental University.  
 
Microarray analysis 
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Total RNA was extracted using standard protocols (Affymetrix). Targets were prepared 
and hybridized to GeneChip Human Gene 1.0 ST arrays (Affymetrix), according to 
standard protocols. GeneChip data sets were analyzed using GeneSpring GX 7.3.1 
(Agilent). Array data were normalized using robust multi-array analysis considering 
guanine and cytosine content algorithms (18). This result was assigned the GEO 
accession number GSE69762. 
 
Immunohistochemistry  
Immunohistochemical analysis of human small intestine was conducted using paraffin-
embedded and frozen sections. Tissue sections were stained following microwave 
treatment (500W, 10 min) in 10 mM citrate buffer. An Atoh1 antibody, originally 
generated by immunizing rabbits with Atoh1 peptide, were used as previously 
described(17). Anti-HD6 (Atlas Antibodies) and anti-β-catenin (BD Biosciences) 
antibodies were also used. Primary antibodies were visualized using secondary 
antibodies conjugated to either Alexa-594 or Alexa-488 (Life Technologies). Sections 
were mounted using VectaShield mounting medium containing DAPI (Vector 
Laboratories) and visualized by confocal laser fluorescent microscopy (FLUOVIEW 
FV10i;Olympus) as previously described(19). 
 
Statistical Analyses  
Quantitative real-time PCR analyses were statistically analyzed using the Student’s t-
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test. P-values <0.05 were considered statistically significant. In the cases of more than 
two data sets existed, differences between groups were determined using one-way 
analysis of variance (ANOVA) and Bonferroni’s post hoc method of multiple 
comparisons. 
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Results 
Atoh1 upregulates HD6 expression and transcriptional activity  
To assess the expression of Paneth cell phenotypic genes in response to Atoh1, we 
transiently transfected the ATOH1 gene into SW480 cells, resulting in marked 
upregulation of HD6 only in response to Atoh1 (Fig. 1a). We therefore investigated the 
HD6 promoter region. As there are three TCF4-binding sites and four E-box-binding 
sites within 1000 bp of the HD6 promoter region (Fig. 1b), we constructed two reporter 
plasmids to assess HD6 transcriptional activity (Fig. 1c). Reporter analysis 
demonstrated significant upregulation of HD6 transcriptional activity by Atoh1 within 
241 bp of the HD6 promoter region in addition to 1000 bp of the HD6 promoter region 
(Fig. 1d). 
 
An E-box-binding site within the HD6 promoter is crucial for the transcriptional 
regulation by Atoh1  
We then investigated the three TCF-binding sites within 1000 bp of the HD6 promoter 
region has previously been reported to be regulated by β-catenin via TCF-binding sites. 
Deletion mutation of the TCF-binding sites demonstrated the TCF-binding site at 178 
bp (T3) was significantly affected transcriptional regulation of HD6 by Atoh1 (Fig. 2a). 
As Atoh1 recognizes and binds to the E-box sequence(20), we constructed E-box 
deletion mutants of HD6 reporter plasmids. Deletion mutation of the E-box-binding site 
demonstrated the E-box-binding site at 101 bp (E3) significantly affected transcriptional 
regulation of HD6 by Atoh1 (Fig. 2b). Deletion of both T3 and E3 resulted in 
significantly decreased HD6 transcriptional activity compared to individual deletions 
(Fig. 2c), indicating that E3 and T3 may be crucial for Atoh1-induced HD6 expression.  
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Atoh1 directly binds to the HD6 promoter region  
We next assessed whether Atoh1 directly binds to the HD6 promoter region. We 
generated stable DLD1 cell lines that strongly expressed Atoh1 protein as previously 
described (mCherry 5SA Atoh1)(16). We then designed primers for ChIP assays as 
shown in Fig. 3a. ChIP assays demonstrated the direct binding of Atoh1 within 200 bp 
of the HD6 promoter region (Fig. 3b). 
 
β-catenin regulates HD6 expression in cooperation with Atoh1  
As DLD1 and SW480 cells are generated from human colon cancer with APC gene 
deletions, nuclear accumulation of β-catenin protein is observed in these cells. The 
presence of β-catenin alone was not found to induce HD6 expression (Fig. 1a). We 
therefore assessed the effect of β-catenin on Atoh1-induced HD6 expression. Treatment 
with calphostin C, an inhibitor of the binding of β-catenin to TCF4, resulted in 
decreased levels of cyclin D1. Treatment of Atoh1-expressing cells with calphostin C 
led to decreased HD6 expression with no effect on TCF4 expression (Fig. 4a). 
Calphostin C also caused decreased Atoh1-induced HD6 transcriptional activity (Fig. 
4b). Interestingly, calphostin C was shown to decrease transcriptional activity in 
response to the TCF4-binding site deletion mutant, indicating β-catenin may regulate 
HD6 expression via the E-box biding site (E3) in cooperation with Atoh1 (Fig. 4c). 
 
 Atoh1 protein colocalizes with β-catenin in HD6-expressing Paneth cells 
We next assessed the localization of Atoh1 and β-catenin in human Paneth cells. β-
catenin was found to be expressed in the nuclei of crypt base cells, whereas Atoh1 was 
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expressed in the nuclei of almost all epithelial cells (Fig. 5a). Double immunostaining 
for HD6 and Atoh1 also demonstrated nuclear expression of Atoh1 in HD6-expressing 
cells (Fig. 5b). Double immunostaining for HD6 and β-catenin demonstrated nuclear 
accumulation of β-catenin in HD6-expressing cells demonstrating colocalization of 
Atoh1 and β-catenin in HD6 expressing Paneth cells (Fig. 5c). Moreover, double 
immunostaining for HD5 and β-catenin demonstrated nuclear accumulation of β-catenin 
in HD5-expressing cells demonstrating colocalization of Atoh1 and β-catenin in HD5 
expressing Paneth cells (Fig. 5d). Furthermore, double immunostaining for HD5 and 
HD6 demonstrated that HD6 and HD5 were expressed in the same cells in almost 
Paneth cells (Supplementary Figure S1a). However, HD6 single positive cell was 
detected in some crypts (Supplementary Figure S1b). 
 
The HD6 expression is decreased in non-inflamed jejunum of CD patients due to 
impaired nuclear accumulation of β-catenin  
Finally, we assessed HD6 expression in biopsy specimens from CD patients. To 
exclude the effect of inflammation, we performed microarray analysis using biopsy 
specimens (Supplementary Table S3). No significant upregulation of inflammation-
related genes were detected in jejunal tissue from CD patients compared to non-IBD 
patients, whereas numerous inflammation-related genes were increased in biopsies 
taken from throughout the ileum of CD patients, suggesting that the jejunal state might 
reflect CD pathogenesis of intestinal epithelial cells without mucosal damage by the 
inflammation. No significant difference in the number of Paneth cells per crypt was 
observed between jejunal biopsies from CD and non-IBD patients (Figs. 6a,b). 
Interestingly, immunostaining for HD6 demonstrated markedly decreased levels of HD6 
Page 16 of 74Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
16 
in jejunal samples from CD patients (Fig. 6c). The number of HD6-positive cells per 
crypt was decreased in jejunal biopsies from CD patients. There was no difference in 
the number of HD5-positive cells per crypt between jejunal samples from CD and non-
IBD patients (Figs. 6d,e). HD6-expressing cells were found to be entirely absent in a 
proportion of crypts in jejunal samples from CD patients (Fig 6d). We therefore further 
assessed the mechanisms underlying the presence of 8 HD6-negative crypts in 6 CD 
patients. Immunostaining demonstrated nuclear accumulation of β-catenin was impaired 
in all HD6-negative crypts, whereas nuclear expression of Atoh1 was observed in all 
cells (Fig. 6f) (Supplementary Figure S2).   
 
Discussion  
This study demonstrated regulation of HD6 expression by the binding of Atoh1 to an 
E-box-binding site in cooperation with β-catenin binding to a TCF4-binding site and an 
E-box-binding site in the HD6 promoter region. We further demonstrated decreased 
levels of HD6 in non-inflamed jejunal biopsy samples from CD patients due to impaired 
nuclear localization of β-catenin, but not Atoh1.   
Previous studies have suggested β-catenin might regulate the HD6 expression in a 
similar manner to HD5 as β-catenin has also been shown to bind to the HD6 promoter 
region(21). However, β-catenin has yet to be shown to promote HD6 expression. 
Although ATOH1 expression is crucial for differentiation toward secretary cell lineages, 
including Paneth cells(22), whether ATOH1 also regulates expression of Paneth 
phenotypic genes remains unknown. In the present study, we demonstrate for the first 
time that HD6 expression is directly regulated by Atoh1 in cooperation with β-catenin. 
We further identified critical sequences allowing binding of Atoh1 and β-catenin to the 
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HD6 promoter region resulting in HD6 gene transcription. Treatment with calphostin C, 
a β-catenin inhibitor, completely inhibited the expression and transcriptional activity of 
HD6. Deletion of the TCF4-binding site partially blocked the transcriptional activity of 
HD6, indicating β-catenin might regulate HD6 transcriptional activity via E-box-
binding site in cooperation with Atoh1, in addition to binding to the TCF4-binding site. 
The interaction between Atoh1 and β-catenin remains unclear with more detailed future 
studies required to fully elucidate their contribution to the regulation of HD6 expression 
in Paneth cells. Moreover, individual Paneth phenotypic genes encoding products, such 
as HD5, lysozyme, and sPLA2 may be independently regulated suggesting that Paneth 
cell subtypes may exist that maintain homeostasis throughout the entire small intestine.   
  Interestingly, expression of HD6, but not HD5, was decreased in non-inflamed jejunal 
biopsies from CD patients. We performed gene expression pattern analysis of the entire 
small intestine of non-IBD patients using biopsy specimens collected by balloon-
assisted enteroscopy(17). In this study, we collected biopsy specimens from the entire 
small intestine of CD patients in order to compare gene expression to tissues obtained 
from non-IBD patients. Numerous inflammation-related genes were found to be 
significantly increased in the whole ileum of CD patients compared with samples taken 
from corresponding regions in non-IBD patients. In particular, inflammation-related 
genes were upregulated in the proximal ileum regardless of endoscopic and pathological 
findings. Jejunal non-inflamed mucosa was selected based on endoscopic, pathological, 
and molecular findings to assess the primary pathogenesis of CD. Microarray analysis 
of jejunal tissue from four CD patients demonstrated no upregulation of inflammation-
related genes compared to non-IBD patients. Consequently, we able to demonstrate 
decreased numbers of HD6-positive cells, but not HD5-positive cells, without an 
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inflammatory effect in CD patients. We found the nuclear accumulation of β-catenin 
was impaired in HD6-negative crypts suggesting HD6 expression was suppressed due 
to decreased β-catenin, but not Atoh1, activity while the number of Paneth cells 
remained constant. It has been reported that HD6 is secreted as an oxidized peptide 
from the bottom of crypts into an aerobic environment and can be spontaneously 
reduced upon reaching the reducing environment of the intestinal lumen(13). Therefore, 
mucosal barrier dysfunction may occur in CD patients despite normal pathological 
findings. This process may be particularly relevant in Japanese CD patients with genetic 
variants affecting mucosal barrier function, such as NOD2(23) and ATG16L1(24), as a 
fundamental mechanism underlying the pathogenesis of CD. It should be considered 
that CD treatments may affect non-inflamed mucosa. However, assessment of the 
mucosa prior to the onset of CD using a prospective study is not possible, as we believe 
non-inflamed jejunal mucosa mimics findings prior to CD onset. Large-scale studies 
that include Caucasian and Asian patients are required to confirm this hypothesis.    
  In this study, Atoh1 expression was not altered in jejunum mucosa without the effect of 
inflammation. It has however been reported that HD6 expression was reduced in 
inflamed ileum(25) with aberrant Notch signal activation(26). Because Atoh1 is directly 
suppressed by Hes1 via Notch signaling(14), Atoh1 might be decreased in inflamed 
ileum of CD patients, resulting in the reduced HD6 expression in corporation with the 
impairment of β-catenin. In future, more detailed analysis for Atoh1 expression in 
inflamed ileum is also required to understand the mucosal barrier dysregulation in entire 
small intestine of CD patients.  
  In conclusion, HD6 is required for the nuclear accumulation of both Atoh1 and β-
catenin in Paneth cells. Decreased levels of nuclear β-catenin, but not Atoh1, induce 
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decreased levels of HD6 without impairment of epithelial differentiation toward Paneth 
cells in CD. Further studies of non-inflamed mucosa may further elucidate the 
mechanisms underlying the pathogenesis of CD.  
 
Disclosures: The authors disclose no conflict of interest.
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Figure Legends 
 
Figure 1. Atoh1 up regulates HD6 expression and transcriptional activity  
 (a) mCherry-Atoh1 or GFP was transfected into SW480 cells. After 48 h, the 
expression of human AMPs was determined by RT-PCR. The amount of mRNA 
expression was normalized by β-actin. Statistical analysis was used Student’s t-test. *p 
< 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. (b) Schematic 
representation of the HD6 promoter region. There are three TCF4-binding sites (T/A-
T/A-CAAAG) and four E-box-binding sites (CANNTG) within 1000 bp. (c) Schematic 
representation of HD6 reporter plasmids. We constructed two different lengths of the 
HD6 promoter region, 1000 bp and 241 bp, respectively. Each binding sites were 
numbered. (d) HD6 reporter activity of by Atoh1 was analyzed. Atoh1 significantly 
promoted the reporter activity of a 241-bp HD6 promoter region as well as a 1000-bp 
HD6 promoter region. Statistical analysis was used one-way analysis of variance 
(ANOVA) and Bonferroni’s post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 
3. N.S.: not significant.  
 
Figure 2. An E-box-binding site on HD6 promoter is crucial for the transcriptional 
activity by Atoh1  
 (a) All or each TCF4-binding sites within 1000 bp of the HD6 promoter region were 
deleted by mutagenesis. Each reporter plasmids were transfected with Atoh1 into 
SW480 cells. 48 h after transfection, reporter assay showed significant suppression of 
transcriptional activity in the T3 deletion mutant as well as that in the deletion mutant of 
all TCF4-binding sites. (b) All or each E-box-binding sites within 241 bp of the HD6 
Page 24 of 74Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
24 
promoter region were deleted by mutagenesis. Each reporter plasmids was transfected 
with Atoh1 into SW480 cells. Forty-eight hours after transfection, reporter assay 
showed significant suppression of transcriptional activity in the E3 deletion mutant, 
which was almost identical to that in the deletion mutant of all E-box-binding sites. 
Statistical analysis was used one-way analysis of variance (ANOVA) and Bonferroni’s 
post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant.  
 
Figure 3. Atoh1 directly binds the HD6 promoter region   
 (a) ChIP assay was performed using DLD1 cells with or without mCherry 5SA-Atoh1. 
Each region is indicated by a schematic. (b) Each region was amplified from the 
immunoprecipitant by each antibody. Only the region including the 13–290-bp segment 
of the HD6 promoter (region b) was amplified from the immunoprecipitant by the 
mCherry antibody. H3: anti-histone 3 antibody was used as positive control. 
 
Figure 4. β-catenin also regulates the HD6 expression in cooperation with Atoh1  
(a) β-catenin inhibitors were transfected into mCherry 5SA-Atoh1 DLD1 cells for 48 h. 
The expression of each gene was analyzed by RT-PCR. The amount of mRNA 
expression was normalized by β-actin. Statistical analysis was used Student’s t-test.  *p 
< 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. (b, c) Each reporter 
plasmid was transfected into mCherry 5SA-Atoh1 DLD1 cells with either DMSO or β-
catenin inhibitor. Forty-eight hours after transfection, the reporter activity was assessed. 
Statistical analysis was used one-way analysis of variance (ANOVA) and Bonferroni’s 
post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. 
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Figure 5. Atoh1 protein is colocalized with β-catenin in HD6-expressing Paneth 
cells 
(a) Immunofluorescence double-staining of Atoh1 and β-catenin in human intestine of 
non-IBD patients merged with DAPI showed colocalization of Atoh1 and β-catenin in 
nuclei (arrow head). Scale bar, 10 µm. (b) Immunofluorescence double-staining of HD6 
and Atoh1 in human intestine of non-IBD patients merged with DAPI showed nuclear 
expression of Atoh1 in HD6-expressing cells. Scale bar, 10 µm. (c) 
Immunofluorescence double-staining of HD6 and β-catenin in human intestine of non-
IBD patients merged with DAPI showed nuclear accumulation of β-catenin in HD6-
expressing cells (arrow head). Scale bar, 10 µm. (d) Immunofluorescence double-
staining of HD5 and β-catenin in human intestine of non-IBD patients merged with 
DAPI showed nuclear accumulation of β-catenin in HD5-expressing cells (arrow head). 
Scale bar, 10 µm.   
 
 
Figure 6. HD6 expression decreased in non-inflamed jejunum of CD patients due 
to impairing the nuclear accumulation of β-catenin  
(a) HE-staining of jejunal specimen taken from CD patients or healthy control. Paneth 
cells are located at the base of crypt shown as a cell with large eosinophilic refractile 
granules in cytoplasm. Scale bar, 10 µm. (b) The average number of Paneth cells per a 
crypt in the CD or non-IBD patients. The number of Paneth cells was counted at over 10 
crypts/person. (c) Immunofluorescence analysis of HD6 merged with DAPI in non-
inflamed jejunum of CD or non-IBD patients. Scale bar, left panel; 500 µm, right panel; 
10 µm. (d) The number of HD5- or HD6-positive cells per crypt in the CD or non-IBD 
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patients. The positive crypt of HD5 was investigated in 213 crypts of 9 non-IBD 
patients and 377 crypts of 15 CD patients, respectively. The positive crypt of HD6 was 
investigated in 248 crypts of 9 non-IBD patients and 391 crypts of 15 CD patients, 
respectively. (e) The average number of HD5- or HD6- positive cells per crypt in the 
CD or non-IBD patients. The number of Paneth cells was counted at over 10 
crypts/person. (f) Immunofluorescence analysis of HD6 either with β-catenin or Atoh1 
merged with DAPI in non-inflamed jejunum of CD patients. Nuclear accumulation of β-
catenin was impaired in all HD6 negative crypts. Scale bar, 10 µm. Atoh1 expression 
was not changed despite HD6 expression. Arrow heads point to HD6 positive cells. 
Statistical analysis was used Student’s t-test. **p < 0.01, ***p < 0.001. N.S.: not 
significant.  
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Abstract 
Background & Aims: Mucosal barrier dysfunction is considered a critical component 
of Crohn’s disease (CD) pathogenesis following the identification of susceptibility 
genes. However, the precise mechanism underlying mucosal barrier dysfunction has not 
yet been elucidated. We therefore aimed to elucidate the molecular mechanism 
underlying the expression of human α-defensin 6 (HD6) in CD patients.    
Methods: 
HD6 expression was induced by the transfection of an atonal homolog 1 (Atoh1) 
transgene and was assessed by RT-PCR. The HD6 promoter region targeted by Atoh1 
and β-catenin was determined by reporter analysis and ChIP assay. HD5 / HD6 / Atoh1 
/ β-catenin expression in non-inflamed jejunal samples collected by balloon endoscopy 
from 15 CD and 9 non-IBD patients were assessed by immunofluorescence.  
Results: 
Both promoter activity and gene expression of HD6 was significantly upregulated by 
the Atoh1 transgene in human colonic cancer cell line. We identified a TCF4 binding 
site and an E-box site critical for the regulation of HD6 transcriptional activity by 
directly binding of Atoh1 in the 200-bp HD6 promoter region. The treatment with beta-
catenin inhibitor also decrease of HD6 promoter activity and gene expression. 
Moreover, HD6 expression, but not HD5 expression, was found to be decreased in non-
inflamed jejunal regions from CD patients. In HD6-negative crypts, nuclear 
accumulation of β-catenin was impaired.  
 
Conclusions: 
HD6 expression was found to be regulated by cooperation between Atoh1 and β-catenin 
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within the HD6 promoter region. Down-regulation of HD6 in non-inflamed mucosa 
may contribute to mucosal barrier dysfunction of CD patients. 
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Introduction  
 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the commonest causes of 
inflammatory bowel disease (IBD)(1). In Western countries, there has been a recent 
focus on the contribution of mucosal barrier dysfunction to CD pathogenesis(2) due to 
the discovery of susceptibility genes, including nucleotide-binding oligomerization 
domain-containing protein 2 (NOD2)(3), autophagy-related protein 16-1 (ATG16L1)(4), 
and X-box-binding protein-1 (XBP1)(5). In particular, the function of Paneth cells in 
forming the mucosal barrier against gut microbiota has been considered as a critical 
factor in CD onset(6). Paneth cell function is broadly divided into two categories: the 
recognition of bacteria and the secretion of antimicrobial peptides (AMPs)(7). Although 
various agents are secreted by Paneth cells, the precise mechanism underlying the 
production of individual AMPs has yet to be clarified for the majority of AMPs. We 
previously reported upregulation of sPLA2 expression following activation of Notch 
signaling(8). The expression of human defensin 5 (HD5) is reportedly regulated by 
binding of β-catenin to T-cell-specific transcription factor 4 (TCF4)-binding sites(9). 
Human defensin 6 (HD6) is also a member of the α-defensin family and is expressed by 
Paneth cells(10). Because of poor antibacterial potency, the molecular mechanism 
underlying HD6 expression has yet not been assessed(11). However, HD6 has recently 
been reported to act as a mucosal barrier by forming “nanonets” to trap bacteria(12). 
Furthermore, reduced form of HD6 has been shown to have a bactericidal effect 
because HD6 expression is also important in the formation of the mucosal barrier(13). 
In this study, we aimed to elucidate the molecular mechanism underlying HD6 
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expression and determine the potential role of HD6 in CD pathogenesis. We then 
investigated the mechanisms regulating HD6 transcriptional activity and expression 
contributing to decreased HD6 levels in non-inflamed jejunum of CD patients using 
mapping biopsies of the entire small intestine. 
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Materials and Methods 
 
Cell culture and chemicals 
Human colon cancer-derived SW480 and DLD-1 cells were grown in Dulbecco’s 
modified Eagle medium (Life Technologies, Grand Island, NY, USA) supplemented 
with 10% fetal bovine serum and 0.01% penicillin-streptomycin. Except where 
indicated otherwise, cells were seeded at a density of 5×105 cells/mL in each 
experiment. Cell cultures and plasmid DNA transfections were performed as previously 
described(14). 5µM Calphostin C (Sigma-Aldrich, St. Louis, MO, USA) was added to 
media to inhibit β-catenin/TCF4 complex formation(15). 
 
Plasmids  
An mCherry-Atoh1 vector was generated by inserting the ATOH1 gene into the 
mCherry DNA template PG27188 (DNA 2.0, Menlo Park, CA, USA). An ATOH1 gene 
mutant vector (5SA-Atoh1) was constructed by PCR-mediated mutagenesis by 
replacing nucleotide cording for five serine residues, TCC (160–162) and AGC (172–
174, 328–330, 340–342, 352–354), with nucleotides coding for the alanine residue, 
GCC. The Atoh1-lentivirus vector was generated by inserting the PCR-amplified 
mCherry-Atoh1 or mCherry-5SA-Atoh1 plasmid into pLenti 6.4 (Invitrogen) as 
previously described(16). Lentiviruses were generated according to the procedure 
manual. A HD6 reporter plasmid was generated by cloning a 1000- and 241-bp 
sequence of the human HD6 gene, HD6, into a pGL4 basic vector (Promega, Madison, 
WI, USA). A mutant HD6 promoter was constructed using polymerase chain reaction 
(PCR)-mediated mutagenesis to delete TCF4-binding sites and E-box sites. The primer 
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sequences used in this study are summarized in Supplementary Table S1. 
 
 
Quantitative Real-time PCR  
Total RNA was isolated using an RNeasy Micro Kit (QIAGEN), according to the 
manufacturer’s instructions. One-microgram aliquots of total RNA were used for cDNA 
synthesis in 20 µl reaction volumes. One microliter of cDNA was amplified with 
SYBR-Green in 20 µl reactions as previously described(14). The primer sequences used 
in this study are summarized in Supplementary Table S1. The amount of mRNA 
expression was normalized by β-actin.  
 
 
Luciferase Assays  
SW480 cells were seeded in six-well plate culture dishes and transfected with 4 µg of 
reporter plasmid along with 10 ng of pRL-TK plasmid (Promega). Cells were harvested 
36 h after transfection, lysed by three cycles of freezing and thawing, and the luciferase 
activities of each sample, measured in arbitrary units, were normalized against Renilla 
luciferase activities as previously described(14).  
 
Chromatin Immunoprecipitation (ChIP) Assay  
ChIP assays were performed as previously described with some modifications. DLD1 
and DLD1-mCherry-Atoh1-5SA cells were seeded onto a 150-mm dish. 
Immunoprecipitation was performed overnight at 4°C with 10 µg of an anti-mCherry 
(Clontech, USA), normal mouse immunoglobulin G (sc-2025; Santa Cruz 
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Biotechnology, Santa Cruz, CA, USA), or an anti-histone H3 antibody (Abcam, 
Cambridge, MA, USA). Genomic DNA fragments in immunoprecipitated samples were 
analyzed by PCR using primers designed against genomic DNA regions relative to the 
translation start site (Supplementary Table S1). Equal amounts of DNA samples were 
analyzed by conventional PCR in parallel using the following parameters: denaturation 
at 94°C for 15 s; annealing at 60°C for 30 s; and extension at 68°C for 60 s for 45 
cycles. Products were resolved by agarose gel electrophoresis, stained with ethidium 
bromide, and visualized using an ImageQuant TL system (GE Healthcare, Milwaukee, 
WI, USA).  
 
Human Small Intestinal Tissue  
Human tissue specimens were obtained from 15 CD and 9 non-IBD patients with an 
indication to undergo double balloon endoscopy or single balloon endoscopy at Tokyo 
Medical and Dental University Hospital. Patient’s information is shown in 
Supplementary Table S2. Non-IBD patients were performed endoscopy because of the 
obscure gastrointestinal bleeding. To analyze the structure of normal small intestine, we 
selected biopsy specimens from non-IBD patients who showed no abnormality in small 
intestine(17). Written informed consent was obtained from all included patients and this 
study was approved by the Ethics Committee of Tokyo Medical and Dental University.  
 
Microarray analysis 
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Total RNA was extracted using standard protocols (Affymetrix). Targets were prepared 
and hybridized to GeneChip Human Gene 1.0 ST arrays (Affymetrix), according to 
standard protocols. GeneChip data sets were analyzed using GeneSpring GX 7.3.1 
(Agilent). Array data were normalized using robust multi-array analysis considering 
guanine and cytosine content algorithms (18). This result was assigned the GEO 
accession number GSE69762. 
 
Immunohistochemistry  
Immunohistochemical analysis of human small intestine was conducted using paraffin-
embedded and frozen sections. Tissue sections were stained following microwave 
treatment (500W, 10 min) in 10 mM citrate buffer. An Atoh1 antibody, originally 
generated by immunizing rabbits with Atoh1 peptide, were used as previously 
described(17). Anti-HD6 (Atlas Antibodies) and anti-β-catenin (BD Biosciences) 
antibodies were also used. Primary antibodies were visualized using secondary 
antibodies conjugated to either Alexa-594 or Alexa-488 (Life Technologies). Sections 
were mounted using VectaShield mounting medium containing DAPI (Vector 
Laboratories) and visualized by confocal laser fluorescent microscopy (FLUOVIEW 
FV10i;Olympus) as previously described(19). 
 
Statistical Analyses  
Quantitative real-time PCR analyses were statistically analyzed using the Student’s t-
Page 38 of 74Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
test. P-values <0.05 were considered statistically significant. In the cases of more than 
two data sets existed, differences between groups were determined using one-way 
analysis of variance (ANOVA) and Bonferroni’s post hoc method of multiple 
comparisons. 
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Results 
Atoh1 upregulates HD6 expression and transcriptional activity  
To assess the expression of Paneth cell phenotypic genes in response to Atoh1, we 
transiently transfected the ATOH1 gene into SW480 cells, resulting in marked 
upregulation of HD6 only in response to Atoh1 (Fig. 1a). We therefore investigated the 
HD6 promoter region. As there are three TCF4-binding sites and four E-box-binding 
sites within 1000 bp of the HD6 promoter region (Fig. 1b), we constructed two reporter 
plasmids to assess HD6 transcriptional activity (Fig. 1c). Reporter analysis 
demonstrated significant upregulation of HD6 transcriptional activity by Atoh1 within 
241 bp of the HD6 promoter region in addition to 1000 bp of the HD6 promoter region 
(Fig. 1d). 
 
An E-box-binding site within the HD6 promoter is crucial for the transcriptional 
regulation by Atoh1  
We then investigated the three TCF-binding sites within 1000 bp of the HD6 promoter 
region has previously been reported to be regulated by β-catenin via TCF-binding sites. 
Deletion mutation of the TCF-binding sites demonstrated the TCF-binding site at 178 
bp (T3) was significantly affected transcriptional regulation of HD6 by Atoh1 (Fig. 2a). 
As Atoh1 recognizes and binds to the E-box sequence(20), we constructed E-box 
deletion mutants of HD6 reporter plasmids. Deletion mutation of the E-box-binding site 
demonstrated the E-box-binding site at 101 bp (E3) significantly affected transcriptional 
regulation of HD6 by Atoh1 (Fig. 2b). Deletion of both T3 and E3 resulted in 
significantly decreased HD6 transcriptional activity compared to individual deletions 
(Fig. 2c), indicating that E3 and T3 may be crucial for Atoh1-induced HD6 expression.  
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Atoh1 directly binds to the HD6 promoter region  
We next assessed whether Atoh1 directly binds to the HD6 promoter region. We 
generated stable DLD1 cell lines that strongly expressed Atoh1 protein as previously 
described (mCherry 5SA Atoh1)(16). We then designed primers for ChIP assays as 
shown in Fig. 3a. ChIP assays demonstrated the direct binding of Atoh1 within 200 bp 
of the HD6 promoter region (Fig. 3b). 
 
β-catenin regulates HD6 expression in cooperation with Atoh1  
As DLD1 and SW480 cells are generated from human colon cancer with APC gene 
deletions, nuclear accumulation of β-catenin protein is observed in these cells. The 
presence of β-catenin alone was not found to induce HD6 expression (Fig. 1a). We 
therefore assessed the effect of β-catenin on Atoh1-induced HD6 expression. Treatment 
with calphostin C, an inhibitor of the binding of β-catenin to TCF4, resulted in 
decreased levels of cyclin D1. Treatment of Atoh1-expressing cells with calphostin C 
led to decreased HD6 expression with no effect on TCF4 expression (Fig. 4a). 
Calphostin C also caused decreased Atoh1-induced HD6 transcriptional activity (Fig. 
4b). Interestingly, calphostin C was shown to decrease transcriptional activity in 
response to the TCF4-binding site deletion mutant, indicating β-catenin may regulate 
HD6 expression via the E-box biding site (E3) in cooperation with Atoh1 (Fig. 4c). 
 
 Atoh1 protein colocalizes with β-catenin in HD6-expressing Paneth cells 
We next assessed the localization of Atoh1 and β-catenin in human Paneth cells. β-
catenin was found to be expressed in the nuclei of crypt base cells, whereas Atoh1 was 
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expressed in the nuclei of almost all epithelial cells (Fig. 5a). Double immunostaining 
for HD6 and Atoh1 also demonstrated nuclear expression of Atoh1 in HD6-expressing 
cells (Fig. 5b). Double immunostaining for HD6 and β-catenin demonstrated nuclear 
accumulation of β-catenin in HD6-expressing cells demonstrating colocalization of 
Atoh1 and β-catenin in HD6 expressing Paneth cells (Fig. 5c). Moreover, double 
immunostaining for HD5 and β-catenin demonstrated nuclear accumulation of β-catenin 
in HD5-expressing cells demonstrating colocalization of Atoh1 and β-catenin in HD5 
expressing Paneth cells (Fig. 5d). Furthermore, double immunostaining for HD5 and 
HD6 demonstrated that HD6 and HD5 were expressed in the same cells in almost 
Paneth cells (Supplementary Figure S1a). However, HD6 single positive cell was 
detected in some crypts (Supplementary Figure S1b). 
 
The HD6 expression is decreased in non-inflamed jejunum of CD patients due to 
impaired nuclear accumulation of β-catenin  
Finally, we assessed HD6 expression in biopsy specimens from CD patients. To 
exclude the effect of inflammation, we performed microarray analysis using biopsy 
specimens (Supplementary Table S3). No significant upregulation of inflammation-
related genes were detected in jejunal tissue from CD patients compared to non-IBD 
patients, whereas numerous inflammation-related genes were increased in biopsies 
taken from throughout the ileum of CD patients, suggesting that the jejunal state might 
reflect CD pathogenesis of intestinal epithelial cells without mucosal damage by the 
inflammation. No significant difference in the number of Paneth cells per crypt was 
observed between jejunal biopsies from CD and non-IBD patients (Figs. 6a,b). 
Interestingly, immunostaining for HD6 demonstrated markedly decreased levels of HD6 
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in jejunal samples from CD patients (Fig. 6c). The number of HD6-positive cells per 
crypt was decreased in jejunal biopsies from CD patients. There was no difference in 
the number of HD5-positive cells per crypt between jejunal samples from CD and non-
IBD patients (Figs. 6d,e). HD6-expressing cells were found to be entirely absent in a 
proportion of crypts in jejunal samples from CD patients (Fig 6d). We therefore further 
assessed the mechanisms underlying the presence of 8 HD6-negative crypts in 6 CD 
patients. Immunostaining demonstrated nuclear accumulation of β-catenin was impaired 
in all HD6-negative crypts, whereas nuclear expression of Atoh1 was observed in all 
cells (Fig. 6f) (Supplementary Figure S2).   
 
Discussion  
This study demonstrated regulation of HD6 expression by the binding of Atoh1 to an 
E-box-binding site in cooperation with β-catenin binding to a TCF4-binding site and an 
E-box-binding site in the HD6 promoter region. We further demonstrated decreased 
levels of HD6 in non-inflamed jejunal biopsy samples from CD patients due to impaired 
nuclear localization of β-catenin, but not Atoh1.   
Previous studies have suggested β-catenin might regulate the HD6 expression in a 
similar manner to HD5 as β-catenin has also been shown to bind to the HD6 promoter 
region(21). However, β-catenin has yet to be shown to promote HD6 expression. 
Although ATOH1 expression is crucial for differentiation toward secretary cell lineages, 
including Paneth cells(22), whether ATOH1 also regulates expression of Paneth 
phenotypic genes remains unknown. In the present study, we demonstrate for the first 
time that HD6 expression is directly regulated by Atoh1 in cooperation with β-catenin. 
We further identified critical sequences allowing binding of Atoh1 and β-catenin to the 
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HD6 promoter region resulting in HD6 gene transcription. Treatment with calphostin C, 
a β-catenin inhibitor, completely inhibited the expression and transcriptional activity of 
HD6. Deletion of the TCF4-binding site partially blocked the transcriptional activity of 
HD6, indicating β-catenin might regulate HD6 transcriptional activity via E-box-
binding site in cooperation with Atoh1, in addition to binding to the TCF4-binding site. 
The interaction between Atoh1 and β-catenin remains unclear with more detailed future 
studies required to fully elucidate their contribution to the regulation of HD6 expression 
in Paneth cells. Moreover, individual Paneth phenotypic genes encoding products, such 
as HD5, lysozyme, and sPLA2 may be independently regulated suggesting that Paneth 
cell subtypes may exist that maintain homeostasis throughout the entire small intestine.   
  Interestingly, expression of HD6, but not HD5, was decreased in non-inflamed jejunal 
biopsies from CD patients. We performed gene expression pattern analysis of the entire 
small intestine of non-IBD patients using biopsy specimens collected by balloon-
assisted enteroscopy(17). In this study, we collected biopsy specimens from the entire 
small intestine of CD patients in order to compare gene expression to tissues obtained 
from non-IBD patients. Numerous inflammation-related genes were found to be 
significantly increased in the whole ileum of CD patients compared with samples taken 
from corresponding regions in non-IBD patients. In particular, inflammation-related 
genes were upregulated in the proximal ileum regardless of endoscopic and pathological 
findings. Jejunal non-inflamed mucosa was selected based on endoscopic, pathological, 
and molecular findings to assess the primary pathogenesis of CD. Microarray analysis 
of jejunal tissue from four CD patients demonstrated no upregulation of inflammation-
related genes compared to non-IBD patients. Consequently, we able to demonstrate 
decreased numbers of HD6-positive cells, but not HD5-positive cells, without an 
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inflammatory effect in CD patients. We found the nuclear accumulation of β-catenin 
was impaired in HD6-negative crypts suggesting HD6 expression was suppressed due 
to decreased β-catenin, but not Atoh1, activity while the number of Paneth cells 
remained constant. It has been reported that HD6 is secreted as an oxidized peptide 
from the bottom of crypts into an aerobic environment and can be spontaneously 
reduced upon reaching the reducing environment of the intestinal lumen(13). Therefore, 
mucosal barrier dysfunction may occur in CD patients despite normal pathological 
findings. This process may be particularly relevant in Japanese CD patients with genetic 
variants affecting mucosal barrier function, such as NOD2(23) and ATG16L1(24), as a 
fundamental mechanism underlying the pathogenesis of CD. It should be considered 
that CD treatments may affect non-inflamed mucosa. However, assessment of the 
mucosa prior to the onset of CD using a prospective study is not possible, as we believe 
non-inflamed jejunal mucosa mimics findings prior to CD onset. Large-scale studies 
that include Caucasian and Asian patients are required to confirm this hypothesis.    
  In this study, Atoh1 expression was not altered in jejunum mucosa without the effect of 
inflammation. It has however been reported that HD6 expression was reduced in 
inflamed ileum(25) with aberrant Notch signal activation(26). Because Atoh1 is directly 
suppressed by Hes1 via Notch signaling(14), Atoh1 might be decreased in inflamed 
ileum of CD patients, resulting in the reduced HD6 expression in corporation with the 
impairment of β-catenin. In future, more detailed analysis for Atoh1 expression in 
inflamed ileum is also required to understand the mucosal barrier dysregulation in entire 
small intestine of CD patients.  
  In conclusion, HD6 is required for the nuclear accumulation of both Atoh1 and β-
catenin in Paneth cells. Decreased levels of nuclear β-catenin, but not Atoh1, induce 
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decreased levels of HD6 without impairment of epithelial differentiation toward Paneth 
cells in CD. Further studies of non-inflamed mucosa may further elucidate the 
mechanisms underlying the pathogenesis of CD.  
 
Disclosures: The authors disclose no conflict of interest.
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Figure Legends 
 
Figure 1. Atoh1 up regulates HD6 expression and transcriptional activity  
 (a) mCherry-Atoh1 or GFP was transfected into SW480 cells. After 48 h, the 
expression of human AMPs was determined by RT-PCR. The amount of mRNA 
expression was normalized by β-actin. Statistical analysis was used Student’s t-test. *p 
< 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. (b) Schematic 
representation of the HD6 promoter region. There are three TCF4-binding sites (T/A-
T/A-CAAAG) and four E-box-binding sites (CANNTG) within 1000 bp. (c) Schematic 
representation of HD6 reporter plasmids. We constructed two different lengths of the 
HD6 promoter region, 1000 bp and 241 bp, respectively. Each binding sites were 
numbered. (d) HD6 reporter activity of by Atoh1 was analyzed. Atoh1 significantly 
promoted the reporter activity of a 241-bp HD6 promoter region as well as a 1000-bp 
HD6 promoter region. Statistical analysis was used one-way analysis of variance 
(ANOVA) and Bonferroni’s post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 
3. N.S.: not significant.  
 
Figure 2. An E-box-binding site on HD6 promoter is crucial for the transcriptional 
activity by Atoh1  
 (a) All or each TCF4-binding sites within 1000 bp of the HD6 promoter region were 
deleted by mutagenesis. Each reporter plasmids were transfected with Atoh1 into 
SW480 cells. 48 h after transfection, reporter assay showed significant suppression of 
transcriptional activity in the T3 deletion mutant as well as that in the deletion mutant of 
all TCF4-binding sites. (b) All or each E-box-binding sites within 241 bp of the HD6 
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promoter region were deleted by mutagenesis. Each reporter plasmids was transfected 
with Atoh1 into SW480 cells. Forty-eight hours after transfection, reporter assay 
showed significant suppression of transcriptional activity in the E3 deletion mutant, 
which was almost identical to that in the deletion mutant of all E-box-binding sites. 
Statistical analysis was used one-way analysis of variance (ANOVA) and Bonferroni’s 
post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant.  
 
Figure 3. Atoh1 directly binds the HD6 promoter region   
 (a) ChIP assay was performed using DLD1 cells with or without mCherry 5SA-Atoh1. 
Each region is indicated by a schematic. (b) Each region was amplified from the 
immunoprecipitant by each antibody. Only the region including the 13–290-bp segment 
of the HD6 promoter (region b) was amplified from the immunoprecipitant by the 
mCherry antibody. H3: anti-histone 3 antibody was used as positive control. 
 
Figure 4. β-catenin also regulates the HD6 expression in cooperation with Atoh1  
(a) β-catenin inhibitors were transfected into mCherry 5SA-Atoh1 DLD1 cells for 48 h. 
The expression of each gene was analyzed by RT-PCR. The amount of mRNA 
expression was normalized by β-actin. Statistical analysis was used Student’s t-test.  *p 
< 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. (b, c) Each reporter 
plasmid was transfected into mCherry 5SA-Atoh1 DLD1 cells with either DMSO or β-
catenin inhibitor. Forty-eight hours after transfection, the reporter activity was assessed. 
Statistical analysis was used one-way analysis of variance (ANOVA) and Bonferroni’s 
post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. 
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Figure 5. Atoh1 protein is colocalized with β-catenin in HD6-expressing Paneth 
cells 
(a) Immunofluorescence double-staining of Atoh1 and β-catenin in human intestine of 
non-IBD patients merged with DAPI showed colocalization of Atoh1 and β-catenin in 
nuclei (arrow head). Scale bar, 10 µm. (b) Immunofluorescence double-staining of HD6 
and Atoh1 in human intestine of non-IBD patients merged with DAPI showed nuclear 
expression of Atoh1 in HD6-expressing cells. Scale bar, 10 µm. (c) 
Immunofluorescence double-staining of HD6 and β-catenin in human intestine of non-
IBD patients merged with DAPI showed nuclear accumulation of β-catenin in HD6-
expressing cells (arrow head). Scale bar, 10 µm. (d) Immunofluorescence double-
staining of HD5 and β-catenin in human intestine of non-IBD patients merged with 
DAPI showed nuclear accumulation of β-catenin in HD5-expressing cells (arrow head). 
Scale bar, 10 µm.   
 
 
Figure 6. HD6 expression decreased in non-inflamed jejunum of CD patients due 
to impairing the nuclear accumulation of β-catenin  
(a) HE-staining of jejunal specimen taken from CD patients or healthy control. Paneth 
cells are located at the base of crypt shown as a cell with large eosinophilic refractile 
granules in cytoplasm. Scale bar, 10 µm. (b) The average number of Paneth cells per a 
crypt in the CD or non-IBD patients. The number of Paneth cells was counted at over 10 
crypts/person. (c) Immunofluorescence analysis of HD6 merged with DAPI in non-
inflamed jejunum of CD or non-IBD patients. Scale bar, left panel; 500 µm, right panel; 
10 µm. (d) The number of HD5- or HD6-positive cells per crypt in the CD or non-IBD 
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patients. The positive crypt of HD5 was investigated in 213 crypts of 9 non-IBD 
patients and 377 crypts of 15 CD patients, respectively. The positive crypt of HD6 was 
investigated in 248 crypts of 9 non-IBD patients and 391 crypts of 15 CD patients, 
respectively. (e) The average number of HD5- or HD6- positive cells per crypt in the 
CD or non-IBD patients. The number of Paneth cells was counted at over 10 
crypts/person. (f) Immunofluorescence analysis of HD6 either with β-catenin or Atoh1 
merged with DAPI in non-inflamed jejunum of CD patients. Nuclear accumulation of β-
catenin was impaired in all HD6 negative crypts. Scale bar, 10 µm. Atoh1 expression 
was not changed despite HD6 expression. Arrow heads point to HD6 positive cells. 
Statistical analysis was used Student’s t-test. **p < 0.01, ***p < 0.001. N.S.: not 
significant.  
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Figure 1. Atoh1 up regulates HD6 expression and transcriptional activity  
(a) mCherry-Atoh1 or GFP was transfected into SW480 cells. After 48 h, the expression of human AMPs was 
determined by RT-PCR. The amount of mRNA expression was normalized by β-actin. Statistical analysis was 
used Student’s t-test. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. (b) Schematic 
representation of the HD6 promoter region. There are three TCF4-binding sites (T/A-T/A-CAAAG) and four 
E-box-binding sites (CANNTG) within 1000 bp. (c) Schematic representation of HD6 reporter plasmids. We 
constructed two different lengths of the HD6 promoter region, 1000 bp and 241 bp, respectively. Each 
binding sites were numbered. (d) HD6 reporter activity of by Atoh1 was analyzed. Atoh1 significantly 
promoted the reporter activity of a 241-bp HD6 promoter region as well as a 1000-bp HD6 promoter region. 
Statistical analysis was used one-way analysis of variance (ANOVA) and Bonferroni’s post hoc method. *p < 
0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant.  
190x266mm (300 x 300 DPI)  
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Figure 2. An E-box-binding site on HD6 promoter is crucial for the transcriptional activity by Atoh1  
(a) All or each TCF4-binding sites within 1000 bp of the HD6 promoter region were deleted by mutagenesis. 
Each reporter plasmids were transfected with Atoh1 into SW480 cells. 48 h after transfection, reporter assay 
showed significant suppression of transcriptional activity in the T3 deletion mutant as well as that in the 
deletion mutant of all TCF4-binding sites. (b) All or each E-box-binding sites within 241 bp of the HD6 
promoter region were deleted by mutagenesis. Each reporter plasmids was transfected with Atoh1 into 
SW480 cells. Forty-eight hours after transfection, reporter assay showed significant suppression of 
transcriptional activity in the E3 deletion mutant, which was almost identical to that in the deletion mutant 
of all E-box-binding sites. Statistical analysis was used one-way analysis of variance (ANOVA) and 
Bonferroni’s post hoc method. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant.  
181x189mm (300 x 300 DPI)  
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Figure 3. Atoh1 directly binds the HD6 promoter region    
(a) ChIP assay was performed using DLD1 cells with or without mCherry 5SA-Atoh1. Each region is indicated 
by a schematic. (b) Each region was amplified from the immunoprecipitant by each antibody. Only the 
region including the 13–290-bp segment of the HD6 promoter (region b) was amplified from the 
immunoprecipitant by the mCherry antibody. H3: anti-histone 3 antibody was used as positive control.  
178x133mm (300 x 300 DPI)  
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Figure 4. β-catenin also regulates the HD6 expression in cooperation with Atoh1  
(a) β-catenin inhibitors were transfected into mCherry 5SA-Atoh1 DLD1 cells for 48 h. The expression of 
each gene was analyzed by RT-PCR. The amount of mRNA expression was normalized by β-actin. Statistical 
analysis was used Student’s t-test.  *p < 0.05, **p < 0.01, ***p < 0.001, n = 3. N.S.: not significant. (b, 
c) Each reporter plasmid was transfected into mCherry 5SA-Atoh1 DLD1 cells with either DMSO or β-catenin 
inhibitor. Forty-eight hours after transfection, the reporter activity was assessed. Statistical analysis was 
used one-way analysis of variance (ANOVA) and Bonferroni’s post hoc method. *p < 0.05, **p < 0.01, ***p 
< 0.001, n = 3. N.S.: not significant.  
165x198mm (300 x 300 DPI)  
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Figure 5. Atoh1 protein is colocalized with β-catenin in HD6-expressing Paneth cells 
(a) Immunofluorescence double-staining of Atoh1 and β-catenin in human intestine of non-IBD patients 
merged with DAPI showed colocalization of Atoh1 and β-catenin in nuclei (arrow head). Scale bar, 10 µm. 
(b) Immunofluorescence double-staining of HD6 and Atoh1 in human intestine of non-IBD patients merged 
with DAPI showed nuclear expression of Atoh1 in HD6-expressing cells. Scale bar, 10 µm. (c) 
Immunofluorescence double-staining of HD6 and β-catenin in human intestine of non-IBD patients merged 
with DAPI showed nuclear accumulation of β-catenin in HD6-expressing cells (arrow head). Scale bar, 10 
µm. (d) Immunofluorescence double-staining of HD5 and β-catenin in human intestine of non-IBD patients 
merged with DAPI showed nuclear accumulation of β-catenin in HD5-expressing cells (arrow head). Scale 
bar, 10 µm.    
185x187mm (300 x 300 DPI)  
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Figure 6. HD6 expression decreased in non-inflamed jejunum of CD patients due to impairing the nuclear 
accumulation of β-catenin  
(a) HE-staining of jejunal specimen taken from CD patients or healthy control. Paneth cells are located at 
the base of crypt shown as a cell with large eosinophilic refractile granules in cytoplasm. Scale bar, 10 µm. 
(b) The average number of Paneth cells per a crypt in the CD or non-IBD patients. The number of Paneth 
cells was counted at over 10 crypts/person. (c) Immunofluorescence analysis of HD6 merged with DAPI in 
non-inflamed jejunum of CD or non-IBD patients. Scale bar, left panel; 500 µm, right panel; 10 µm. (d) The 
number of HD5- or HD6-positive cells per crypt in the CD or non-IBD patients. The positive crypt of HD5 was 
investigated in 213 crypts of 9 non-IBD patients and 377 crypts of 15 CD patients, respectively. The positive 
crypt of HD6 was investigated in 248 crypts of 9 non-IBD patients and 391 crypts of 15 CD patients, 
respectively. (e) The average number of HD5- or HD6- positive cells per crypt in the CD or non-IBD 
patients. The number of Paneth cells was counted at over 10 crypts/person. (f) Immunofluorescence 
analysis of HD6 either with β-catenin or Atoh1 merged with DAPI in non-inflamed jejunum of CD patients. 
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Nuclear accumulation of β-catenin was impaired in all HD6 negative crypts. Scale bar, 10 µm. Atoh1 
expression was not changed despite HD6 expression. Arrow heads point to HD6 positive cells. Statistical 
analysis was used Student’s t-test. **p < 0.01, ***p < 0.001. N.S.: not significant.  
197x286mm (300 x 300 DPI)  
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Supplementary Figure S1 
(a) Immunofluorescence double-staining of HD5 and HD6 in human intestine of non-IBD patients merged 
with DAPI showed co-localization of HD5 and HD6. Scale bar, 10 µm. 
(b) In some crypts, HD6 single positive cells were shown. Scale bar, 10 µm.  
159x131mm (300 x 300 DPI)  
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Supplementary Figure S2 
(a) Immunofluorescence analysis of HD6 either with β-catenin merged with DAPI in non-inflamed jejunum of 
the other CD patient to Figure 6f. Nuclear accumulation of β-catenin was impaired only in HD6 negative 
crypt. Scale bar, 50 µm. 
(b) High magnification image of HD6 positive crypt. Nuclear accumulation of β-catenin was shown in HD6 
positive cell (arrow head). Scale bar, 10 µm. 
(c) High magnification image of HD6 negative crypt. The nuclear localization of β-catenin is not shown in all 
cells. Scale bar, 10 µm.  
186x148mm (300 x 300 DPI)  
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Hayashi et al. Supplementary Table S1 
 
Quantitative analysis 
 Primer Sequence 
Gene Forward Reverse 
HD5 5’ GCCATCCTTGCTGCCATTC 3’ 5’ TGATTTCACACACCCCGGAGA 3’ 
HD6 5’ CCTCACCATCCTCACTGCTGTTC 3’ 5’ CCATGACAGTGCAGGTCCCATA 3’ 
Lysozyme 5’ CTCTCATTGTTCTGGGGC 3’ 5’ ACGGACAACCCTCTTTGC 3’ 
PLA2G2A 5’ ACCATGAAGACCCTCCTACTG 3’ 5’ GAAGAGGGGACTCAGCAACG 3’ 
cyclin D1 5’ AGGCTGGTGGCAAGTGCACG 3’ 5’ TGTTGGTGCTGGGAAGCGCC 3’ 
TCF4 5’ ATCGTCCCAGAGTGATGTCG 3’ 5’ CGGGCCAGCTCGTAGTATTT 3’ 
β-actin 5’ GGATGCAGAAGGAGATCACTG 3’ 5’ CGATCCACACGGAGTACTTG 3’ 
 
 
Construction of HD6 Promoter 
 Primer Sequence 
Gene Forward Reverse 
HD6 (T1 del) 5’GTCAATTGTTTCGATGTTTTGGAGAGAAATACCTAGTA
C3’ 
5’GTACTAGGTATTTCTCTCCAAAACATCGAAACAATTGAC3’ 
HD6 (T2 del) 5’CAAGAGCCTATTCACCCCATAATCCTCCTTCATGAGGG
C3’ 
5’GCCCTCATGAAGGAGGATTATGGGGTGAATAGGCTCTTG3’ 
HD6 (T3 del) 5’TCACACTACAATGAAGCTTGGAGAAGGGACATGGAGG
GCA3’ 
5’TGCCCTCCATGTCCCTTCTCCAAGCTTCATTGTAGTGTGA3’ 
HD6 (E1 del) 5’ CGGGGTACCGGACCAGAACAGACACTCAAT 3’ 5’ AGTCAGTCAGCGAGAGCAGGAGCAGA 3’ 
HD6 (E2 del) 5’CCCAATCACACACTCCCCGTCTCACCGCAACATCTGT
CCC3’ 
5’GGGACAGATGTTGCGGTGAGACGGGGAGTGTGTGATTGGG
3’ 
HD6 (E3 del) 5’TCACATGCACTCCCCGTCTCACCGCAACATCTCCCTG
AGCCTTC3’ 
5’GAAGGCTCAGGGAGATGTTGCGGTGAGACGGGGAGTGCAT
GTGA3’ 
HD6 (E4 del) 5’CTGGCTCCTCACTCCCCTCTGCTCCTGCTCTCTCTCC
TC 3’ 
5’GAGGAGAGAGAGCAGGAGCAGAGGGGAGTGAGGAGCCAG3
’ 
HD6 Kpn1 1000 5’ AGTCAGTCGGTACCTGGACCCTTCTCTTT 3’  
HD6 kpn1 200 5’ CGGGGTACCCAGCTGGGACCAGAACAGACA 3’  
3’ NheⅠ HD6  5’ AGTCAGTCAGCGAGAGCAGGAGCAGA 3’  
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ChiP assay 
 Primer Sequence 
gene Forward Reverse 
 HD6 (-4123 -3852) 5' CCATCCAAGACGGTGAAAGT 3’ 5’ TGGTCCCAATTCTTGGACTC 3’ 
 HD6 (-290 -13) 5' CCAGCAGATGGAAAACAGGA 3’ 5’ TGGAGGAGAGAGAGCAGGAG 3’ 
 
Page 65 of 74 Inflammatory Bowel Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Hayashi et al. Supplementary Table S2 
 
 non-IBD (n=9) Crohn’s Disease (n=15) 
Mean Age (y.o.) (range) 60.8 (37-80) 29.5 (19-60) 
Gender   
  Male 5 (55.6%) 13 (86.7%) 
  Female 4 (44.4%)  2 (13.3%) 
Location of disease   
  Ileitis  2 (13.3%) 
  Colitis  0 (0%) 
  Ileocolitis  13 (86.7%) 
Treatment   
  Anti-TNFα therapy  7 (46.7%) 
  Immunomodulator  7 (46.7%) 
  Steroid  0 (0%) 
  5-ASA  10 (66.7%) 
 
 
Supplementary Table S2 legend 
 
Patient’s information in this study. Non-IBD patients were performed balloon 
endoscopy because of the obscure gastrointestinal bleeding. To analyze the structure of 
normal small intestine, we selected non-IBD patients who showed no abnormality in 
small intestine by balloon endoscopy. 
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Hayashi et al. Supplementary Table S3 
 
Jejunum UP 
 
 Identifiler Gene title Fold Change  p 
 NM_012128 CLCA4  3.2  0.06 
 NM_014080 DUOX2  3.0  0.07 
 NM_001040442 FABP6 2.6  0.14 
 NM_197975 BTNL3  2.5  0.09 
 NM_006890 CEACAM7  2.4  0.16 
 NR_006880|NR_003271 SNORD3A|SNORD3B-1 2.2  0.00002 
 |NR_003924|NR_006881|NR_006882 |SNORD3B-2|SNORD3C|SNORD3D  
 NR_006880|NR_003271 SNORD3A|SNORD3B-1 2.2  0.00002 
 |NR_003924|NR_006881|NR_006882 |SNORD3B-2|SNORD3C|SNORD3D  
 NR_006880|NR_003271 SNORD3A|SNORD3B-1 2.2  0.00003 
 |NR_003924|NR_006881|NR_006882 |SNORD3B-2|SNORD3C|SNORD3D  
 NR_006880|NR_003271 SNORD3A|SNORD3B-1 2.2  0.00002 
 |NR_003924|NR_006881|NR_006882 |SNORD3B-2|SNORD3C|SNORD3D  
 NR_006880|NR_003271 SNORD3A|SNORD3B-1 2.2  0.00003 
 |NR_003924|NR_006881|NR_006882 |SNORD3B-2|SNORD3C|SNORD3D  
 NM_004591|NM_001130046 CCL20  2.2 0.03 
 NM_005564 LCN2  2.1  0.09 
 NM_002964 S100A8  2.1  0.08 
 NM_001018016  MUC1  2.1  0.13 
 NM_001828  CLC  2.0  0.005 
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Jejunum DOWN 
 
 Identifiler Gene title Fold change p 
 NM_001076|NM_001077  UGT2B15|UGT2B17 -5.6 0.009 
 NM_001076|NM_001077  UGT2B15|UGT2B17 -5.6 0.009
 NM_001807  CEL -5.6 0.06 
 NM_001077  UGT2B17 -3.6 0.007 
 NM_017460  CYP3A4 -2.9 0.11 
 NM_001074  UGT2B7 -2.8 0.002 
 NM_004617  TM4SF4 -2.5 0.10 
 NM_002021  FMO1 -2.5 0.08 
 NM_000771  CYP2C9 -2.5 0.02 
 NM_000040  APOC3 -2.5 0.04 
 NM_080669|NM_015077  SLC46A1|SARM1|TMEM199 -2.4 0.06 
 NM_000039  APOA1 -2.4 0.008 
 NM_000040  APOC3 -2.4 0.05 
 NM_000039  APOA1 -2.4 0.09 
 NM_000769  CYP2C19 -2.4 0.006 
 NM_080429  AQP10 -2.4 0.06 
 NM_002555  SLC22A18 -2.3 0.002 
 NM_019893|NM_001079516|XM_927086 ASAH2|ASAH2B|ASAH2C -2.3 0.05 
NM_019893|NM_001079516|XM_927086 ASAH2|ASAH2B|ASAH2C -2.3 0.08 
 NM_001081 CUBN -2.3 0.14 
 NM_003167 SULT2A1 -2.3 0.06 
 NM_020716  GRAMD1B -2.2 0.03 
 NM_001045  SLC6A4 -2.2 0.05 
 NM_006424  SLC34A2 -2.2 0.01 
 NM_001001548  CD36 -2.2 0.04 
 NM_007180  TREH -2.1 0.07 
 NM_006159  NELL2 -2.1 0.03 
 NM_022444  SLC13A1 -2.1 0.13 
 NM_000482 APOA4 -2.1 0.02 
NM_019893|NM_001079516|XM_927086 ASAH2|ASAH2B|ASAH2C -2.1 0.07 
 NM_019601 SUSD2 -2.1 0.05 
 NM_001003954  ANXA13 -2.1 0.02 
 NM_000482  APOA4 -2.1 0.13 
 NM_002299 LCT -2.1 0.14 
 NM_004212  SLC28A2 -2.1 0.007 
 NM_000384 APOB -2.1 0.22 
 NM_002242 KCNJ13 -2.0 0.19 
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 NM_145176  SLC2A12 -2.0 0.07 
 NM_005518  HMGCS2 -2.0 0.11 
 NM_000340  SLC2A2 -2.0 0.07 
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Ileum UP 
 
 Identifiler Gene title Fold change p 
 NM_004476 FOLH1 7.5  0.02  
  LOC652493 5.7  0.02  
  IGKV3D-11 4.6  0.04  
  VSIG6 4.4  0.01  
 XM_002345544 IGKV3D-15|IGKV3-20|IGKV3D-11 4.3  0.04  
  VSIG6|IGHA2|IGHG1 3.9  0.01  
  HLA-DQB1 3.8  0.0001  
  HLA-DQB1 3.8  0.00008  
 NM_000064 C3 3.6  0.03  
  IGKC 3.6  0.03  
 NM_002123|NM_002124 HLA-DQB1|HLA-DRB1 3.5  0.005  
 NM_180991 SLCO4C1 3.4  0.05  
 NM_001778 CD48 3.4  0.03  
  IGHV4-31|IGHA2|IGHA1|IGHG3 |IGHD 3.4  0.03 
  |IGHM|IGHG1|IGHG2|IGHG4|IGHV3-23   
 NM_000063 C2 3.3  0.00006  
 NM_000063 C2 3.3  0.00008  
 NM_000063 C2 3.3  0.00007  
  IGKC 3.3  0.05  
 NM_000560 CD53 3.3  0.04  
 NM_021814 ELOVL5 3.2  0.04  
 NM_021181 SLAMF7 3.2  0.05  
  IGKC 3.2  0.04  
 NM_002122 HLA-DQA1 3.1  0.0004  
  IGKC 3.1  0.03  
 NM_002185 IL7R 3.1  0.03  
  IGHA1 3.0  0.03  
  HLA-DQB1 3.0  0.0001  
  LOC100291056 3.0  0.04  
 NM_001774 CD37 3.0  0.04  
 NM_002121 HLA-DPB1 3.0  0.01  
 NM_148672 CCL28 2.9  0.002  
 NM_006573 TNFSF13B 2.9  0.04   
 NM_033554 HLA-DPA1 2.8  0.02  
 NM_033554 HLA-DPA1 2.8  0.02  
 NM_033554 HLA-DPA1 2.8  0.01  
  PTPRC 2.8  0.04  
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 NM_052931 SLAMF6 2.7  0.01  
 NM_002121 HLA-DPB1 2.7  0.01  
 NM_052941 GBP4 2.7  0.04  
 NM_007074 CORO1A 2.7  0.03  
 NM_001242 CD27 2.6  0.03  
 NM_002615 SERPINF1 2.6  0.03  
 NM_007293|NM_001002029 C4A|C4B 2.6  0.04  
 NM_007293|NM_001002029 C4A|C4B 2.6  0.04  
 NM_007293|NM_001002029 C4A|C4B 2.6  0.04  
 NM_002121 HLA-DPB1 2.6  0.00  
 NM_002738 PRKCB 2.6  0.04  
  IGHA1 2.5  0.05  
 NM_002298 LCP1 2.5  0.05  
  IGHM 2.5  0.04  
 NM_001465 FYB 2.5  0.05  
 NM_145799 SEPT6 2.5  0.02  
 NM_002872 RAC2 2.5  0.03  
  IGKC|IGKV3D-15 2.5  0.03  
 NM_004862 LITAF 2.4  0.04  
 NM_006762 LAPTM5 2.4  0.05  
 NM_003650 CST7 2.4  0.05  
 NM_004536 NAIP 2.4  0.05   
  IGKC 2.4  0.05  
  LOC100293211 2.3  0.05  
 NM_031419 NFKBIZ 2.3  0.04  
 NM_002209 ITGAL 2.3  0.03  
 NM_004536 NAIP 2.3  0.05  
 NM_004536 NAIP 2.3  0.05  
 NM_004310 RHOH 2.3  0.04  
  IGLJ3|IGHV3-23|IGHG1 2.3  0.04  
 NM_002120 HLA-DOB|TAP2 2.3  0.05  
 NM_001155 ANXA6 2.3  0.01  
 NM_001628 AKR1B1 2.3  0.03  
 NM_001130080 IFI27 2.2  0.002  
 NM_018326 GIMAP4 2.2  0.03  
  IGHA1|IGHG1 2.2  0.04  
 NM_006674 HCP5 2.2  0.0002  
 NM_020056|NM_002122 HLA-DQA2|HLA-DQA1 2.2  0.01  
 NM_002120 HLA-DOB|TAP2 2.2  0.05  
  IGHD|IGHG1| 2.2  0.04  
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 NM_020056|NM_002122 HLA-DQA2|HLA-DQA1 2.1  0.01  
 NM_001098526 AMICA1 2.1  0.02  
 NM_000310 PPT1 2.1  0.01  
 NM_000204 CFI 2.1  0.02  
 NM_014800 ELMO1 2.1  0.05  
 NM_181671 PITPNC1 2.1  0.03  
 NR_003937 HLA-DQB2 2.1  0.003  
 NM_004811 LPXN 2.1  0.02  
 NM_000732 CD3D 2.1  0.04  
 NM_000073 CD3G 2.1  0.04  
 NR_003937 HLA-DQB2 2.1  0.01  
 NM_005063 SCD 2.1  0.02  
 NM_001003927 EVI2A 2.1  0.05  
 NM_002017|NM_001167681 FLI1|EWSR1 2.1  0.04  
 NM_005739 RASGRP1 2.1  0.005  
 NM_005608 PTPRCAP 2.1  0.005  
 NM_018384 GIMAP5 2.0  0.001  
 NM_006060 IKZF1 2.0  0.01  
 NM_001164315|NM_025190 ANKRD36|ANKRD36B 2.0  0.04  
 NM_001803 CD52 2.0  0.02  
 NM_000439 PCSK1 2.0  0.03  
 NM_018456 EAF2 2.0  0.01  
 NM_001040153 SLAIN1 2.0  0.02  
 NM_005337 NCKAP1L 2.0  0.01 
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Ileum DOWN 
 
Identifiler Gene title Fold change p 
 NM_001807 CEL -14.1  0.03  
 NM_022444 SLC13A1 -13.5  0.04  
 NM_001040442 FABP6 -10.4  0.13  
 NM_206832 TMIGD1 -7.7  0.07  
 NM_153021 PLB1 -6.8  0.09  
 NM_004617 TM4SF4 -6.5  0.21  
 NM_001081 CUBN -6.4  0.06  
 NM_153237 C9orf71 -6.3  0.04  
 NM_001076|NM_001077 UGT2B15|UGT2B17 -5.8  0.14  
 NM_001076|NM_001077 UGT2B15|UGT2B17 -5.8  0.15  
 NM_001077 UGT2B17 -4.8  0.07  
 NM_033100 CDHR1|PCDH21 -4.2  0.04  
 NM_000767 CYP2B6 -4.1  0.05  
 NM_002555|NM_183233 SLC22A18 -4.0  0.01  
 NM_019893|NM_001079516 ASAH2|ASAH2B|ASAH2C -3.9  0.02  
 NM_019893|NM_001079516 ASAH2|ASAH2B|ASAH2C -3.9  0.30  
 NM_033553 GUCA2A -3.9  0.14  
 NM_001074 UGT2B7 -3.7  0.16  
 NM_000111 SLC26A3 -3.7  0.11  
 NM_173077 CPO -3.7  0.16  
 NM_017460 CYP3A4 -3.7  0.37  
 NM_001142462 OSR2 -3.7  0.03  
 NM_019893|NM_001079516 ASAH2|ASAH2B|ASAH2C -3.5  0.26  
 NM_001115131 C6 -3.5  0.02  
 NM_000777 CYP3A5 -3.5  0.11  
 NM_005518 HMGCS2 -3.5  0.26  
 NM_004212 SLC28A2 -3.3  0.38  
 NM_207373 C10orf99 -3.3  0.22  
 NM_001045 SLC6A4 -3.2  0.24  
 NM_000384 APOB -3.1  0.30  
 NM_206893 MS4A10 -3.1  0.37  
 NM_004827 ABCG2 -3.1  0.26  
 NM_001086 AADAC -3.1  0.28  
 NM_001003954 ANXA13 -3.1  0.26  
 NM_000482 APOA4 -3.0  0.34  
 NM_001945 HBEGF -3.0  0.19  
 NM_178498 SLC5A12 -3.0  0.35  
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 NM_005073 SLC15A1 -3.0  0.20  
 NM_000482 APOA4 -3.0  0.34  
 NM_000340 SLC2A2 -3.0  0.26  
 NM_000452 SLC10A2 -3.0  0.29  
 NM_006424 SLC34A2 -3.0  0.10  
 NM_000040 APOC3 -2.9  0.18  
 NM_017662 TRPM6 -2.9  0.07  
 NM_000040 APOC3 -2.9  0.27  
 NM_001164462 MUC12 -2.9  0.04  
 NM_021969 NR0B2 -2.9  0.07  
 NM_000039 APOA1 -2.9  0.13  
 NM_005925 MEP1B -2.9  0.32  
 NM_000770 CYP2C8|CYP2C19 -2.9  0.04  
 NM_000039 APOA1 -2.9  0.36  
 NM_080877 SLC34A3 -2.9  0.002  
 NM_147161|NM_176782 ACOT11|FAM151A -2.8  0.15  
 NM_001003841 SLC6A19 -2.8  0.31  
 NM_001074 UGT2B7 -2.7  0.28  
 NM_019601 SUSD2 -2.7  0.23  
 NM_001164462 MUC12 -2.7  0.01  
 NM_001146108 PTGR1 -2.7  0.15  
 NM_173354 SIK1 -2.7  0.04  
 NM_000392 ABCC2 -2.6  0.23  
 NM_001977 ENPEP -2.6  0.24  
 NM_013381 TRHDE -2.5  0.13  
 NM_016591 GCNT4 -2.5  0.32  
 NM_004164 RBP2 -2.5  0.40  
 NM_000927 ABCB1 -2.5  0.19  
 NM_004205 USP2 -2.5  0.09  
 NM_020299 AKR1B10 -2.5  0.26  
 NM_003167 SULT2A1 -2.5  0.36  
 NM_007102 GUCA2B -2.5  0.17  
 NM_001142564 CNGA1 -2.5  0.001  
 NM_001944 DSG3 -2.5  0.004  
 NM_000898 MAOB -2.4  0.31  
 NM_032607 CREB3L3 -2.4  0.31  
 NM_021804 ACE2 -2.4  0.27  
 NM_152338 ZG16 -2.4  0.28  
 NM_000775 CYP2J2 -2.4  0.25  
 NM_001005353 AK3L1 -2.4  0.003  
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 NM_000846 GSTA2 -2.4  0.26  
 NM_014905 GLS -2.4  0.08  
 NM_002458 MUC5B -2.4  0.004  
 NM_020716 GRAMD1B -2.4  0.20  
 NM_014270 SLC7A9 -2.4  0.20  
 NM_002021 FMO1 -2.4  0.23  
 NM_181785 SLC46A3 -2.3  0.17  
 NM_004668 MGAM -2.3  0.20  
 NM_007180 TREH -2.3  0.39  
 NM_032439|NM_001001971 PHYHIPL|FAM13C -2.3  0.26  
 NM_001010893 SLC10A5 -2.3  0.22  
 NM_004696 SLC16A4 -2.3  0.06  
 NM_006259 PRKG2 -2.3  0.26  
 NM_000253 MTTP -2.3  0.34  
 NM_014053 FLVCR1 -2.3  0.23  
 NM_152338 ZG16 -2.3  0.28  
 NM_000151 G6PC -2.3  0.51  
 NM_004170 SLC1A1 -2.3  0.19  
 NM_004133 HNF4G -2.3  0.21  
 NM_024743 UGT2A3 -2.2  0.39  
 NM_173039 AQP11 -2.2  0.24  
 NM_005624 CCL25 -2.2  0.29  
 NM_021187 CYP4F11 -2.2  0.32  
 NM_001631 ALPI -2.2  0.30  
 NM_005562 LAMC2 -2.2  0.04  
 NM_153446 B4GALNT2 -2.2  0.03  
 NM_025047 ARL14 -2.2  0.04  
 NM_002614|NR_003377 PDZK1|PDZK1P1 -2.2  0.26  
 NR_027384 SLC13A2 -2.2  0.38  
 NM_006017 PROM1 -2.2  0.01  
 NM_024743 UGT2A3 -2.2  0.34  
 NM_017675|NM_001171976 CDHR2|PCDH24 -2.2  0.26  
 NM_000112 SLC26A2 -2.1  0.12  
 NM_002639 SERPINB5 -2.1  0.04  
 NM_004235 KLF4 -2.1  0.002  
 NM_004403 DFNA5 -2.1  0.13  
 NM_003783 B3GALT2 -2.1  0.02  
 NM_015888 HOOK1 -2.1  0.07  
 NM_000463|NM_001072|NM_019075 UGT1A1|UGT1A6|UGT1A10  
 |NM_021027|NM_007120|NM_019093 |UGT1A9|UGT1A4|UGT1A3  -2.1  0.29 
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 |NM_019078|NM_019077|NM_019076 |UGT1A5|UGT1A7|UGT1A8  
 NM_014227 SLC5A4 -2.1  0.41  
 NM_015020|NM_001017967 PHLPP2|MARVELD3 -2.1  0.25  
 NM_152622 MIER3 -2.1  0.07  
 NM_024989 PGAP1 -2.1  0.06  
 NM_001082 CYP4F2 -2.1  0.32  
 NM_014471 SPINK4 -2.1  0.12  
 NM_153614 DNAJB13 -2.1  0.08  
 NM_207330 NIPAL1 -2.1  0.06  
 NM_001112706 SCIN -2.1  0.19  
 NM_147164 CNTFR -2.1  0.12  
 NM_003399 XPNPEP2 -2.1  0.38  
 NM_013389 NPC1L1 -2.1  0.56  
 NM_018713 SLC30A10 -2.1  0.32  
 NM_182762 MACC1 -2.1  0.16  
 NM_001104554 PAQR5 -2.1  0.13  
 NM_014181 HSPC159 -2.1  0.04  
 NM_022901 LRRC19 -2.1  0.13  
 NM_001025356 ANO6 -2.1  0.09  
 NM_000240 MAOA -2.0  0.31  
 NM_001098844 TMEM236 -2.0  0.22  
 NM_001098844 TMEM236 -2.0  0.22  
 NM_006200 PCSK5 -2.0  0.22  
 NM_022436 ABCG5 -2.0  0.41  
 NM_152357 ZNF440 -2.0  0.03  
 NM_004232 SOCS6 -2.0  0.04  
 NM_017878 HRASLS2 -2.0  0.28  
 NM_000949 PRLR -2.0  0.17  
 NM_145034 TOR1AIP2 -2.0  0.17  
 NM_020974 SCUBE2 -2.0  0.23  
  CD36 -2.0  0.43 
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Supplementary Table S3 legend 
 
Microarray analysis 
Total RNA was extracted using standard protocols (Affymetrix). Targets were prepared 
and hybridized to GeneChip Human Gene 1.0 ST arrays (Affymetrix), according to 
standard protocols. GeneChip data sets were analyzed using GeneSpring GX 7.3.1 
(Agilent). Array data were normalized using robust multi-array analysis considering 
guanine and cytosine content algorithms.  
  The gene expression in jejunum was compared between CD (8 samples from 4 
patients) and non-IBD patients (8 samples from 4patients). The gene expression in 
ileum was also compared between CD (4 samples from 2 patients) and non-IBD patients 
(4 samples from 2patients). 
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